Drug Profile
Human papillomavirus vaccine recombinant bivalent - Japan Vaccine/AstraZeneca
Alternative Names: Cervarix; GSK-580299; HPV-16/18 vaccine - Japan Vaccine; Human papillomavirus (types 6, 18) L1 virus-like particle vaccine - Japan Vaccine; Human Papillomavirus 16/18 L1 AS04 virus-like particle cervical cancer vaccine - Japan Vaccine; Human papillomavirus bivalent (types 16, 18) recombinant vaccine - Japan Vaccine; MEDI 517; MEDI-517 HPV-16/18 VLP AS04 vaccineLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator MedImmune
- Developer GlaxoSmithKline; GSK; Japan Vaccine
- Class Cancer vaccines; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Anal cancer; Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Preregistration Submission Withdrawal Head and neck cancer
Most Recent Events
- 27 May 2022 9370550: updated KDM & HE
- 27 May 2022 National Medical Products Administration approves human papillomavirus vaccine recombinant bivalent in girls aged between 9 to 14 years for the prevention of cervical cancer, cervical intraepithelial neoplasia and adenocarcinoma in China
- 22 Oct 2021 Regulatory submission withdrawn for Head and neck cancer (In adolescents, In children, Prevention) in European Union (IM)